SOURCE: OTCPro.com

February 21, 2006 09:57 ET

Morning Movers: INSA, RIMM, VRA, INFO

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by OTCPro.com.

BOCA RATON, FL -- (MARKET WIRE) -- February 21, 2006 -- OTCPro.com announces its list of stocks to watch! (OTC BB: INSA), (NASDAQ: RIMM), (AMEX: VRA), (NASDAQ: INFO): these stocks are looking to move!

OTCPro commenting on its coverage of Invisa Inc, Inc (OTC BB: INSA). INSA has made some interesting announcements of late, hinting at a potential industry wide standardization of its SmartGate Technology for parking gates. Invisa released some great news today. OTCPro.com believes the stock is under accumulation and poised for a major move and risk oriented traders and investors should look for a suitable entry point.

Invisa Inc. (OTC BB: INSA) today announced that 2005 was their largest unit sales year to date. Sales and units sold for the year 2005 increased by 21% and 34%, respectively, over 2004. Our sales from units for the year 2005 totaled $239,285 on 754 units. For the year 2004, such sales totaled $197,484 on 561 units sold. They also achieved additional penetration into the valued safety market for their products. This penetration reflects a growing number of parking gate manufacturers promoting their SmartGate® brand safety products and integrating their products as original equipment into their parking gates. They also continued to implement our plans to launch our first security product in 2006.

Research In Motion (RIM) (NASDAQ: RIMM); Judge May Soon Issue Injunction on BlackBerry Sales As Maker and Patent Holder Continue Dispute. Say what you want about patent infringement suits, but at least the BlackBerry case has drama. A federal judge, clearly impatient with the long-running case, could issue an injunction soon on U.S. sales and service of the wireless e-mail device.

Viragen, Inc. (AMEX: VRA) and its majority-owned subsidiary, Viragen International, Inc., today announced that the Swedish Medical Products Agency (MPA) approved Multiferon® (multi-subtype, natural human alpha interferon) for the first-line adjuvant treatment of high-risk (Stages IIb-III) malignant melanoma following dacarbazine (DTIC) after surgical removal of tumors. Viragen will officially launch this new malignant melanoma indication this month.

Metro One Telecommunications, Inc. (NASDAQ: INFO): UP 21% in pre-market trading.

Morning Commentary:

"With gold being higher, oil back over $61 and the dollar up, we're surprisingly looking at a higher opening, so I kind of expect it's going to be any good news out of the retailers that will keep the market afloat," said Peter Cardillo, chief market analyst at S.W. Bach & Co.

U.S. markets were closed on Monday for Presidents Day.

S&P 500 futures were up 2.8 points, above fair value, a mathematical formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract.

Dow Jones industrial average futures rose 39 points, and Nasdaq 100 futures were up 6 points.

A sharp jump in the price of crude oil could hamper stocks' gains. Crude shot up $1.53 to $61.34 a barrel as militant attacks shut a fifth of Nigeria's oil production.

About OTCPro.com

OTCPro.com is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. OTCPros is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. OTCPro's goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. OTCPro provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. OTCPros offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.OTCPro.com.

OTCP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of an OTCP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an OTCP opinion, recommendation or analysis. Information regarding companies which OTCP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that OTCP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating OTCP's statements regarding a company. An affiliate of OTCP has been rehired by Invisa Inc. and compensated fifty thousand dollars and five hundred thousand warrants exercisable at. $40 cents for six month coverage and was previously hired by GM Capital. OTCP and affiliates have no other relationship to companies. This should be construed as a potential conflict of interest. OTCP's officers and directors reserve the right to buy additional shares of the company discussed in this opinion and may profit in the event those shares rise in value. When OTCP receives free trading shares as compensation for a profiled company, OTCP may sell part or all of any such shares during the period in which OTCP is performing such services.

Contact Information